Stryker (NYSE:SYK - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Thursday, July 31st. Analysts expect Stryker to post earnings of $3.06 per share and revenue of $5.92 billion for the quarter. Stryker has set its FY 2025 guidance at 13.200-13.450 EPS.
Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion for the quarter, compared to analysts' expectations of $5.68 billion. During the same quarter last year, the company earned $2.50 EPS. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.
Stryker Price Performance
Stryker stock traded up $6.68 during trading on Friday, reaching $403.34. The company had a trading volume of 963,567 shares, compared to its average volume of 1,155,846. The firm's 50-day simple moving average is $386.37 and its 200 day simple moving average is $379.33. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The firm has a market capitalization of $153.95 billion, a PE ratio of 54.51, a price-to-earnings-growth ratio of 2.99 and a beta of 0.91. Stryker has a 1-year low of $314.93 and a 1-year high of $406.19.
Stryker Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.83%. Stryker's payout ratio is currently 45.41%.
Analysts Set New Price Targets
A number of research analysts have weighed in on the company. BTIG Research restated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Citigroup reiterated a "buy" rating and set a $455.00 price target (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Roth Mkm lifted their price target on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Evercore ISI lifted their price target on Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Finally, Sanford C. Bernstein set a $450.00 price target on Stryker in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $428.55.
View Our Latest Stock Analysis on SYK
Insider Activity at Stryker
In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director directly owned 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 5.90% of the company's stock.
Institutional Investors Weigh In On Stryker
An institutional investor recently raised its position in Stryker stock. Brighton Jones LLC lifted its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,564 shares of the medical technology company's stock after purchasing an additional 609 shares during the period. Brighton Jones LLC's holdings in Stryker were worth $1,643,000 at the end of the most recent quarter. Institutional investors and hedge funds own 77.09% of the company's stock.
Stryker Company Profile
(
Get Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
See Also
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
